Last synced on 30 May 2025 at 11:05 pm

High Throughput Dna Sequencing For Hereditary Cancer Predisposition Assessment Test System.

Page Type
Product Code
Definition
A high throughput DNA sequencing for hereditary cancer predisposition assessment test system is a qualitative in vitro diagnostic (IVD) system intended for analysis of human DNA extracted from human specimens to detect germline mutations in a panel of targeted cancer related genes. It is intended to aid in hereditary cancer predisposition assessment by qualified health care professionals in accordance with professional guidelines. The device is not intended for screening, prenatal testing or as a stand-alone diagnostic test. The device is for prescription use only.
Physical State
The test system consists of reagents, DNA sequencing detection methods, and software. Should not include devices intended for over-the-counter use, intended to aid in diagnosis, prognosis or screening of cancer, pre-natal screening, or intended to make or recommend treatment decisions.
Technical Method
The test system uses high-throughput sequencing technology to amplify, detect, and identify nucleic acid variants located in specified genes associated with hereditary cancer predisposition. Variants are identified based on de novo sequencing or by comparison to a specified reference sequence. The test system may also include confirmatory testing for certain variants. Genetic predisposition assessment of developing certain cancers is based on scientifically established disease-risk association for each variant.
Target Area
Human peripheral whole blood or other clinical samples
Regulation Medical Specialty
Pathology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6095
GMP Exempt?
No
Summary Malfunction Reporting
Ineligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

Product code QVU is linked to regulation 21CFR866.6095, which does not seem to exist yet. It may be pending at the moment.

High Throughput Dna Sequencing For Hereditary Cancer Predisposition Assessment Test System.

Page Type
Product Code
Definition
A high throughput DNA sequencing for hereditary cancer predisposition assessment test system is a qualitative in vitro diagnostic (IVD) system intended for analysis of human DNA extracted from human specimens to detect germline mutations in a panel of targeted cancer related genes. It is intended to aid in hereditary cancer predisposition assessment by qualified health care professionals in accordance with professional guidelines. The device is not intended for screening, prenatal testing or as a stand-alone diagnostic test. The device is for prescription use only.
Physical State
The test system consists of reagents, DNA sequencing detection methods, and software. Should not include devices intended for over-the-counter use, intended to aid in diagnosis, prognosis or screening of cancer, pre-natal screening, or intended to make or recommend treatment decisions.
Technical Method
The test system uses high-throughput sequencing technology to amplify, detect, and identify nucleic acid variants located in specified genes associated with hereditary cancer predisposition. Variants are identified based on de novo sequencing or by comparison to a specified reference sequence. The test system may also include confirmatory testing for certain variants. Genetic predisposition assessment of developing certain cancers is based on scientifically established disease-risk association for each variant.
Target Area
Human peripheral whole blood or other clinical samples
Regulation Medical Specialty
Pathology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6095
GMP Exempt?
No
Summary Malfunction Reporting
Ineligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

Product code QVU is linked to regulation 21CFR866.6095, which does not seem to exist yet. It may be pending at the moment.